Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.6%

14 terminated/withdrawn out of 103 trials

Success Rate

81.6%

-5.0% vs industry average

Late-Stage Pipeline

29%

30 trials in Phase 3/4

Results Transparency

55%

34 of 62 completed trials have results

Key Signals

10 recruiting34 with results14 terminated

Enrollment Performance

Analytics

Phase 2

32(32.7%)

Phase 3

28(28.6%)

Phase 1

28(28.6%)

N/A

7(7.1%)

Phase 4

2(2.0%)

Early Phase 1

1(1.0%)

98Total

Phase 2(32)

Phase 3(28)

Phase 1(28)

N/A(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (103)

Showing 20 of 103 trials

NCT03545607Phase 3Terminated

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

Role: collaborator

NCT05291091Phase 2Active Not Recruiting

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Role: collaborator

NCT06066580Phase 2Enrolling By Invitation

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Role: collaborator

NCT07062471Not ApplicableRecruiting

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

Role: collaborator

NCT07512128Not ApplicableNot Yet Recruiting

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)

Role: collaborator

NCT07102511Phase 3Enrolling By Invitation

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Role: collaborator

NCT07605429Phase 3Recruiting

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

Role: collaborator

NCT05983250Phase 3Active Not Recruiting

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Role: collaborator

NCT06564974Recruiting

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Role: collaborator

NCT07702292Phase 2Recruiting

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: collaborator

NCT07432633Phase 1Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: collaborator

NCT03073967Phase 3Completed

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Role: collaborator

NCT07614958Phase 3Recruiting

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Role: collaborator

NCT04979806Phase 3Completed

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Role: collaborator

NCT06777433Phase 2Active Not Recruiting

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Role: collaborator

NCT03624010Phase 2Completed

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Role: collaborator

NCT04329728Phase 1Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies